NASDAQ:VAXX Vaxxinity (VAXX) Stock Price, News & Analysis $0.03 -0.03 (-50.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.01▼$0.3050-Day Range$0.03▼$0.4052-Week Range$0.01▼$2.79Volume32,284 shsAverage Volume1.19 million shsMarket Capitalization$3.80 millionP/E RatioN/ADividend YieldN/APrice Target$7.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Vaxxinity alerts: Email Address Ad The Oxford ClubMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.Watch Alex's "Next Magnificent Seven" presentation now. About Vaxxinity Stock (NASDAQ:VAXX)Vaxxinity, Inc., a biotechnology company, focuses on developing product candidates for human use in the fields of neurology, cardiovascular diseases, and coronaviruses in the United States. Its product pipeline comprises UB-311, which is in phase 2 clinical trial that targets toxic forms of aggregated amyloid-b in the brain to fight alzheimer's disease; UB-312, which is in phase 1 clinical trial that targets toxic forms of aggregated a-synuclein in the brain to fight parkinson's disease and other synucleinopathies, such as Lewy body dementia and multiple system atrophy; and VXX-301, which is in preclinical trial, an anti-tau product candidate for various neurodegenerative conditions, including alzheimer's disease, traumatic brain injury, and chronic traumatic encephalopathy. It also develops VXX-401, which is phase 1 clinical trial that targets proprotein convertase subtilisin/kexin type 9 serine protease to lower low-density lipoprotein cholesterol and reduce the risk of cardiac events; UB-313 that targets calcitonin gene-related peptide to fight migraines; and UB-612, neutralizes the SARS-CoV-2 virus and is in phase 3 clinical trial. The company was incorporated in 2021 and is headquartered in Merritt Island, Florida.Read More VAXX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart VAXX Stock News HeadlinesJune 20, 2024 | globenewswire.comVaxxinity UB-312 Parkinson's Trial Results Published in Nature MedicineMay 3, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Up 39% Today?July 27, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.April 22, 2024 | investorplace.comWhy Is Vaxxinity (VAXX) Stock Down 58% Today?April 19, 2024 | marketwatch.comVaxxinity Plans to Delist Shares From NasdaqApril 19, 2024 | globenewswire.comVaxxinity Issues Shareholder LetterApril 19, 2024 | globenewswire.comVaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockMarch 28, 2024 | globenewswire.comVaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual MeetingJuly 27, 2024 | Monument Traders Alliance (Ad)This student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... In fact, it just detected a move happening this MONDAY.March 27, 2024 | investorplace.comVAXX Stock Earnings: Vaxxinity Beats EPS for Q4 2023March 27, 2024 | globenewswire.comVaxxinity Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdatesMarch 7, 2024 | globenewswire.comVaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson's Disease at AD/PD™ 2024February 15, 2024 | finance.yahoo.comVaxxinity’s Heart Health Innovation to Reduce LDL Cholesterol LevelsFebruary 15, 2024 | finance.yahoo.comVaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 15, 2024 | globenewswire.comVaxxinity's Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data PublishedFebruary 13, 2024 | finance.yahoo.comVaxxinity to Present Clinical and Preclinical Pipeline Data at AD/PD 2024January 30, 2024 | finance.yahoo.comVaxxinity, UF Join Forces Against Neurodegenerative DiseasesJanuary 30, 2024 | finance.yahoo.comVaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of FloridaSee More Headlines Receive VAXX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxxinity and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/27/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:VAXX CUSIPN/A CIK1851657 Webwww.vaxxinity.com Phone254-244-5739FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$7.00 High Stock Price Target$7.00 Low Stock Price Target$7.00 Potential Upside/Downside+23,233.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($0.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-56,930,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-192.58% Return on Assets-88.04% Debt Debt-to-Equity Ratio0.99 Current Ratio1.89 Quick Ratio1.89 Sales & Book Value Annual Sales$70,000.00 Price / Sales54.32 Cash FlowN/A Price / Cash FlowN/A Book Value$0.11 per share Price / Book0.27Miscellaneous Outstanding Shares126,748,000Free Float45,553,000Market Cap$3.80 million OptionableNot Optionable Beta3.26 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Louis Garfield Reese IV (Age 42)Co-Founder & Executive Chairman of the Board Comp: $275.57kMs. Mei Mei Hu J.D. (Age 41)Co-Founder, President, CEO & Director Comp: $345.14kMs. Sumita Ray J.D. (Age 50)Chief Legal, Compliance & Administrative Officer and Corporate Secretary Comp: $465.56kDr. Jean-Cosme Dodart Ph.D.Chief Scientific OfficerMr. Jon HarrisonChief Government OfficerMr. Mark Joinnides MSEChief of StaffMs. Amy B. Fix M.B.A.M.S., R.A.C., Head of RegulatoryMore ExecutivesKey CompetitorsReneo PharmaceuticalsNASDAQ:RPHMLexaria BioscienceNASDAQ:LEXXCarisma TherapeuticsNASDAQ:CARMKezar Life SciencesNASDAQ:KZRNabriva TherapeuticsNASDAQ:NBRVView All CompetitorsInsidersMovers Lab Fund I Lp PrimeSold 25,089 sharesTotal: $41,898.63 ($1.67/share)Movers Lab Fund I Lp PrimeSold 5,308 sharesTotal: $9,979.04 ($1.88/share)View All Insider Transactions VAXX Stock Analysis - Frequently Asked Questions How have VAXX shares performed this year? Vaxxinity's stock was trading at $0.85 at the beginning of the year. Since then, VAXX shares have decreased by 96.5% and is now trading at $0.03. View the best growth stocks for 2024 here. How were Vaxxinity's earnings last quarter? Vaxxinity, Inc. (NASDAQ:VAXX) issued its quarterly earnings data on Monday, March, 27th. The company reported ($0.16) earnings per share for the quarter, meeting the consensus estimate of ($0.16). When did Vaxxinity IPO? Vaxxinity (VAXX) raised $90 million in an initial public offering (IPO) on Thursday, November 11th 2021. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. How do I buy shares of Vaxxinity? Shares of VAXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:VAXX) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.